JP2004527492A - 運動障害の予防もしくは治療における使用のためのカルバメート化合物 - Google Patents
運動障害の予防もしくは治療における使用のためのカルバメート化合物 Download PDFInfo
- Publication number
- JP2004527492A JP2004527492A JP2002567293A JP2002567293A JP2004527492A JP 2004527492 A JP2004527492 A JP 2004527492A JP 2002567293 A JP2002567293 A JP 2002567293A JP 2002567293 A JP2002567293 A JP 2002567293A JP 2004527492 A JP2004527492 A JP 2004527492A
- Authority
- JP
- Japan
- Prior art keywords
- tremor
- group
- formula
- phenyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000016285 Movement disease Diseases 0.000 title claims abstract description 25
- 238000011282 treatment Methods 0.000 title description 21
- 230000002265 prevention Effects 0.000 title description 5
- 150000004657 carbamic acid derivatives Chemical class 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 56
- 150000001875 compounds Chemical class 0.000 claims abstract description 38
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 20
- 239000001257 hydrogen Substances 0.000 claims abstract description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 14
- 239000000460 chlorine Substances 0.000 claims abstract description 14
- 125000001424 substituent group Chemical group 0.000 claims abstract description 10
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 9
- 150000002367 halogens Chemical class 0.000 claims abstract description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 9
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 8
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 8
- 239000011737 fluorine Substances 0.000 claims abstract description 8
- 125000005843 halogen group Chemical group 0.000 claims abstract description 8
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 7
- 239000011630 iodine Substances 0.000 claims abstract description 7
- 206010044565 Tremor Diseases 0.000 claims description 79
- 201000006517 essential tremor Diseases 0.000 claims description 24
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 23
- 206010003591 Ataxia Diseases 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 208000012661 Dyskinesia Diseases 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 15
- 230000001314 paroxysmal effect Effects 0.000 claims description 15
- 206010008748 Chorea Diseases 0.000 claims description 13
- 208000012601 choreatic disease Diseases 0.000 claims description 12
- 208000011580 syndromic disease Diseases 0.000 claims description 9
- 206010010904 Convulsion Diseases 0.000 claims description 8
- 206010038743 Restlessness Diseases 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 230000036461 convulsion Effects 0.000 claims description 7
- 206010034010 Parkinsonism Diseases 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 5
- 208000020431 spinal cord injury Diseases 0.000 claims description 5
- 208000007101 Muscle Cramp Diseases 0.000 claims description 4
- 208000005392 Spasm Diseases 0.000 claims description 4
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 4
- 230000002490 cerebral effect Effects 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 206010002660 Anoxia Diseases 0.000 claims description 3
- 241000976983 Anoxia Species 0.000 claims description 3
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 3
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 3
- 206010021143 Hypoxia Diseases 0.000 claims description 3
- 206010073211 Postural tremor Diseases 0.000 claims description 3
- 208000016620 Tourette disease Diseases 0.000 claims description 3
- 208000018839 Wilson disease Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 230000007953 anoxia Effects 0.000 claims description 3
- 230000002566 clonic effect Effects 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000002269 spontaneous effect Effects 0.000 claims description 3
- 206010022520 Intention tremor Diseases 0.000 claims description 2
- 206010071390 Resting tremor Diseases 0.000 claims description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 2
- 208000013667 paroxysmal dyskinesia Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 12
- 208000005793 Restless legs syndrome Diseases 0.000 description 12
- 239000001961 anticonvulsive agent Substances 0.000 description 11
- RERZNCLIYCABFS-UHFFFAOYSA-N harmaline Chemical compound C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- -1 alkyl carbamate Chemical compound 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 229940125681 anticonvulsant agent Drugs 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000003826 tablet Substances 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 6
- 229960002870 gabapentin Drugs 0.000 description 6
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 5
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 5
- 229960004394 topiramate Drugs 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 208000009017 Athetosis Diseases 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 3
- 229960000623 carbamazepine Drugs 0.000 description 3
- BQYRVMAWJCIIKI-UHFFFAOYSA-N carbamic acid;1-phenylethane-1,2-diol Chemical class NC(O)=O.OCC(O)C1=CC=CC=C1 BQYRVMAWJCIIKI-UHFFFAOYSA-N 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000011458 pharmacological treatment Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical class CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000239290 Araneae Species 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 208000035183 Benign hereditary chorea Diseases 0.000 description 1
- 235000011960 Brassica ruvo Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000033895 Choreoacanthocytosis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- RHVPEFQDYMMNSY-UHFFFAOYSA-N Harmalol Natural products N1C2=CC(O)=CC=C2C2=C1C(C)=NCC2 RHVPEFQDYMMNSY-UHFFFAOYSA-N 0.000 description 1
- 206010064950 Head titubation Diseases 0.000 description 1
- 208000010271 Heart Block Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000667092 Homo sapiens Vacuolar protein sorting-associated protein 13A Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- GFZSXKJIDFDGFF-QMMMGPOBSA-N NC(OC[C@@H](c(cccc1)c1Cl)OC(N)=O)=O Chemical compound NC(OC[C@@H](c(cccc1)c1Cl)OC(N)=O)=O GFZSXKJIDFDGFF-QMMMGPOBSA-N 0.000 description 1
- OLBWFRRUHYQABZ-MRVPVSSYSA-N NC(OC[C@H](c(cccc1)c1Cl)O)=O Chemical compound NC(OC[C@H](c(cccc1)c1Cl)O)=O OLBWFRRUHYQABZ-MRVPVSSYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 102100039114 Vacuolar protein sorting-associated protein 13A Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001977 ataxic effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- 229960000911 benserazide Drugs 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 201000008675 chorea-acanthocytosis Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000003954 decarboxylase inhibitor Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001263 extrapyramidal tract Anatomy 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000007431 neuroacanthocytosis Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27168301P | 2001-02-27 | 2001-02-27 | |
| PCT/US2002/005542 WO2002067926A1 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating movement disorders |
| US10/081,501 US6589985B2 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating movement disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004527492A true JP2004527492A (ja) | 2004-09-09 |
| JP2004527492A5 JP2004527492A5 (enExample) | 2005-12-22 |
Family
ID=26765643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002567293A Pending JP2004527492A (ja) | 2001-02-27 | 2002-02-21 | 運動障害の予防もしくは治療における使用のためのカルバメート化合物 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6589985B2 (enExample) |
| EP (1) | EP1411917B1 (enExample) |
| JP (1) | JP2004527492A (enExample) |
| KR (1) | KR100858232B1 (enExample) |
| CN (1) | CN1262272C (enExample) |
| AR (1) | AR033426A1 (enExample) |
| AT (1) | ATE369130T1 (enExample) |
| AU (1) | AU2002247204B2 (enExample) |
| BR (1) | BR0207831A (enExample) |
| CA (1) | CA2439478C (enExample) |
| CY (1) | CY1106924T1 (enExample) |
| CZ (1) | CZ20032299A3 (enExample) |
| DE (1) | DE60221670T2 (enExample) |
| DK (1) | DK1411917T3 (enExample) |
| ES (1) | ES2291454T3 (enExample) |
| HU (1) | HUP0303344A3 (enExample) |
| IL (2) | IL157592A0 (enExample) |
| MX (1) | MXPA03007719A (enExample) |
| MY (1) | MY157373A (enExample) |
| NO (1) | NO20033803L (enExample) |
| NZ (1) | NZ551954A (enExample) |
| PL (1) | PL364679A1 (enExample) |
| PT (1) | PT1411917E (enExample) |
| RS (1) | RS50676B (enExample) |
| RU (1) | RU2294739C2 (enExample) |
| TW (1) | TWI331524B (enExample) |
| WO (1) | WO2002067926A1 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009502914A (ja) * | 2005-07-26 | 2009-01-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | サブスタンス関連障害を処置する方法 |
| JP2016512232A (ja) * | 2013-03-12 | 2016-04-25 | バイオ−ファーム ソリューションズ カンパニー リミテッド | 運動障害の予防又は治療用フェニルカルバメート化合物 |
| JP2020502137A (ja) * | 2016-12-14 | 2020-01-23 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 振戦又は振戦症候群の予防、軽減又は治療のためのカルバメート化合物の使用 |
| JP2023539291A (ja) * | 2020-08-31 | 2023-09-13 | バイオ－ファーム ソリューションズ カンパニー リミテッド | 神経変性疾患の予防又は治療用フェニルアルキルカルバメート化合物 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1305082E (pt) * | 2000-07-21 | 2004-09-30 | Ortho Mcneil Pharm Inc | Compostos de carbamato para utilizacao na prevencao ou tratamento da dor neuropatica e dor associada a cefaleia de salvas e enxaqueca |
| PT1383489E (pt) * | 2001-02-27 | 2007-06-21 | Ortho Mcneil Pharm Inc | Compostos carbamato para utilização na prevenção ou tratamento de distúrbios neurodegenerativos |
| HUP0401367A2 (hu) | 2001-07-16 | 2004-12-28 | Ortho-Mcneil Pharmaceutical, Inc. | Karbamátvegyületek alkalmazása neuropátiás fájdalom, valamint cluster és migrénes fejfájással társuló fájdalom megelőzésére vagy kezelésére |
| PL1890684T3 (pl) | 2005-06-08 | 2014-05-30 | Sk Biopharmaceuticals Co Ltd | Leczenie zaburzeń snu i czuwania |
| PE20070325A1 (es) * | 2005-06-29 | 2007-05-12 | Alza Corp | Formas de dosificacion oral que comprenden compuestos derivados de carbamato |
| MX2009004798A (es) * | 2006-10-31 | 2009-08-12 | Janssen Pharmaceutica Nv | Tratamiento de los trastornos generalizados del desarrollo. |
| RU2557533C2 (ru) | 2009-11-06 | 2015-07-20 | Ск Биофармасъютиклс Ко., Лтд. | Способы лечения синдрома фибромиалгии |
| ES2447295T3 (es) | 2009-11-06 | 2014-03-11 | Sk Biopharmaceuticals Co., Ltd. | Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) * | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| CN105164103B (zh) | 2013-03-12 | 2019-12-06 | 比皮艾思药物研发有限公司 | 苯基氨基甲酸酯化合物和含有其的预防或治疗记忆缺失相关疾病的组合物 |
| KR102121680B1 (ko) * | 2016-02-29 | 2020-06-10 | (주)바이오팜솔루션즈 | 설파메이트 유도체 화합물, 이의 제조 방법 및 용도 |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| KR20240162165A (ko) | 2017-06-02 | 2024-11-14 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 과다 졸림증을 치료하기 위한 방법 및 조성물 |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| US3265728A (en) | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
| US5698588A (en) | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
-
2002
- 2002-02-21 AT AT02714978T patent/ATE369130T1/de active
- 2002-02-21 PL PL02364679A patent/PL364679A1/xx not_active Application Discontinuation
- 2002-02-21 CN CNB028089243A patent/CN1262272C/zh not_active Expired - Fee Related
- 2002-02-21 US US10/081,501 patent/US6589985B2/en not_active Expired - Fee Related
- 2002-02-21 BR BR0207831-7A patent/BR0207831A/pt not_active Application Discontinuation
- 2002-02-21 PT PT02714978T patent/PT1411917E/pt unknown
- 2002-02-21 ES ES02714978T patent/ES2291454T3/es not_active Expired - Lifetime
- 2002-02-21 JP JP2002567293A patent/JP2004527492A/ja active Pending
- 2002-02-21 NZ NZ551954A patent/NZ551954A/en unknown
- 2002-02-21 AU AU2002247204A patent/AU2002247204B2/en not_active Ceased
- 2002-02-21 WO PCT/US2002/005542 patent/WO2002067926A1/en not_active Ceased
- 2002-02-21 CZ CZ20032299A patent/CZ20032299A3/cs unknown
- 2002-02-21 RU RU2003128985/14A patent/RU2294739C2/ru not_active IP Right Cessation
- 2002-02-21 KR KR1020037011271A patent/KR100858232B1/ko not_active Expired - Fee Related
- 2002-02-21 DE DE60221670T patent/DE60221670T2/de not_active Expired - Lifetime
- 2002-02-21 MX MXPA03007719A patent/MXPA03007719A/es active IP Right Grant
- 2002-02-21 RS YUP-677/03A patent/RS50676B/sr unknown
- 2002-02-21 EP EP02714978A patent/EP1411917B1/en not_active Expired - Lifetime
- 2002-02-21 IL IL15759202A patent/IL157592A0/xx unknown
- 2002-02-21 CA CA2439478A patent/CA2439478C/en not_active Expired - Fee Related
- 2002-02-21 DK DK02714978T patent/DK1411917T3/da active
- 2002-02-21 HU HU0303344A patent/HUP0303344A3/hu unknown
- 2002-02-27 AR ARP020100698A patent/AR033426A1/es unknown
- 2002-02-27 TW TW091103503A patent/TWI331524B/zh not_active IP Right Cessation
- 2002-02-27 MY MYPI20020692A patent/MY157373A/en unknown
-
2003
- 2003-08-26 IL IL157592A patent/IL157592A/en not_active IP Right Cessation
- 2003-08-26 NO NO20033803A patent/NO20033803L/no not_active Application Discontinuation
-
2007
- 2007-10-10 CY CY20071101301T patent/CY1106924T1/el unknown
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009502914A (ja) * | 2005-07-26 | 2009-01-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | サブスタンス関連障害を処置する方法 |
| JP2016512232A (ja) * | 2013-03-12 | 2016-04-25 | バイオ−ファーム ソリューションズ カンパニー リミテッド | 運動障害の予防又は治療用フェニルカルバメート化合物 |
| JP2020502137A (ja) * | 2016-12-14 | 2020-01-23 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 振戦又は振戦症候群の予防、軽減又は治療のためのカルバメート化合物の使用 |
| JP7086076B2 (ja) | 2016-12-14 | 2022-06-17 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 振戦又は振戦症候群の予防、軽減又は治療のためのカルバメート化合物の使用 |
| JP2023539291A (ja) * | 2020-08-31 | 2023-09-13 | バイオ－ファーム ソリューションズ カンパニー リミテッド | 神経変性疾患の予防又は治療用フェニルアルキルカルバメート化合物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004527492A (ja) | 運動障害の予防もしくは治療における使用のためのカルバメート化合物 | |
| AU2002247204A1 (en) | Carbamate compounds for use in preventing or treating movement disorders | |
| US7122576B2 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| US6562867B2 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| AU2002354909B2 (en) | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain | |
| HK1067305B (en) | Carbamate compounds for use in preventing or treating movement disorders | |
| AU2002255580B2 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| AU2002354909A1 (en) | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain | |
| HK1063288B (en) | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain | |
| ZA200401155B (en) | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain. | |
| AU2002255580A1 (en) | Carbamate compounds for use in preventing or treating bipolar disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041130 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041130 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080427 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080715 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080912 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080922 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090109 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090303 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090601 |